{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:34:14Z","timestamp":1786980854138,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T00:00:00Z","timestamp":1615852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T00:00:00Z","timestamp":1615852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s10549-021-06173-z","type":"journal-article","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T15:02:26Z","timestamp":1615906946000},"page":"77-89","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES"],"prefix":"10.1007","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6459-8118","authenticated-orcid":false,"given":"Young-Hyuck","family":"Im","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Karabulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong-Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Adhav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Havva Yesil","family":"Cinkir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikmat","family":"Abdel-Razeq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Ching","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sercan","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeesoo","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Bowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khemaies","family":"Slimane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,16]]},"reference":[{"key":"6173_CR1","unstructured":"Breast cancer, early diagnosis and screening (2020) https:\/\/www.who.int\/cancer\/prevention\/diagnosis-screening\/breast-cancer\/en\/. Accessed 6 Nov 2020"},{"key":"6173_CR2","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10549-019-05318-5","volume":"177","author":"W Yeo","year":"2019","unstructured":"Yeo W, Ueno T, Lin CH, Liu Q, Lee KH, Leung R, Naito Y, Park YH, Im SA, Li H, Yap YS, Lu YS (2019) Treating HR+\/HER2- breast cancer in premenopausal Asian women: Asian breast cancer cooperative group 2019 consensus and position on ovarian suppression. Breast Cancer Res Treat 177:549\u2013559. https:\/\/doi.org\/10.1007\/s10549-019-05318-5","journal-title":"Breast Cancer Res Treat"},{"key":"6173_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ijsu.2006.06.015","volume":"5","author":"NS El Saghir","year":"2007","unstructured":"El Saghir NS, Khalil MK, Eid T, El Kinge AR, Charafeddine M, Geara F, Seoud M, Shamseddine AI (2007) Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg 5:225\u2013233. https:\/\/doi.org\/10.1016\/j.ijsu.2006.06.015","journal-title":"Int J Surg"},{"key":"6173_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.7497\/j.issn.2095-3941.2014.02.005","volume":"11","author":"DR Youlden","year":"2014","unstructured":"Youlden DR, Cramb SM, Yip CH, Baade PD (2014) Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med 11:101\u2013115. https:\/\/doi.org\/10.7497\/j.issn.2095-3941.2014.02.005","journal-title":"Cancer Biol Med"},{"key":"6173_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11523-018-0587-9","volume":"14","author":"S Sammons","year":"2019","unstructured":"Sammons S, Kornblum NS, Blackwell KL (2019) Fulvestrant-based combination therapy for second-line treatment of hormone receptor-positive advanced breast cancer. Target Oncol 14:1\u201312. https:\/\/doi.org\/10.1007\/s11523-018-0587-9","journal-title":"Target Oncol"},{"key":"6173_CR6","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/s41598-018-37472-z","volume":"9","author":"Y Xie","year":"2019","unstructured":"Xie Y, Zhao Y, Gong C, Chen Z, Zhang Y, Zhao Y, Yuan P, Hu S, Li Y, Hu X, Zhang J, Wang L, Wang B (2019) Treatment after progression on fulvestrant among metastatic breast cancer patients in clinical practice: a multicenter. Retrospective study. Sci Rep 9:1710. https:\/\/doi.org\/10.1038\/s41598-018-37472-z","journal-title":"Sci Rep"},{"key":"6173_CR7","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2217\/fon.12.49","volume":"8","author":"JA Beaver","year":"2012","unstructured":"Beaver JA, Park BH (2012) The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol 8:651\u2013657. https:\/\/doi.org\/10.2217\/fon.12.49","journal-title":"Future Oncol"},{"key":"6173_CR8","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMra023246","volume":"348","author":"IE Smith","year":"2003","unstructured":"Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348:2431\u20132442. https:\/\/doi.org\/10.1056\/NEJMra023246","journal-title":"N Engl J Med"},{"key":"6173_CR9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1634\/theoncologist.9-5-489","volume":"9","author":"H Mouridsen","year":"2004","unstructured":"Mouridsen H, Sun Y, Gershanovich M, Perez-Carrion R, Becquart D, Chaudri-Ross HA, Lang R (2004) Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability. Oncologist 9:489\u2013496. https:\/\/doi.org\/10.1634\/theoncologist.9-5-489","journal-title":"Oncologist"},{"key":"6173_CR10","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1200\/jco.2000.18.22.3758","volume":"18","author":"JM Nabholtz","year":"2000","unstructured":"Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex study group. J Clin Oncol 18:3758\u20133767. https:\/\/doi.org\/10.1200\/jco.2000.18.22.3758","journal-title":"J Clin Oncol"},{"key":"6173_CR11","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1200\/jco.2000.18.22.3748","volume":"18","author":"J Bonneterre","year":"2000","unstructured":"Bonneterre J, Th\u00fcrlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 18:3748\u20133757. https:\/\/doi.org\/10.1200\/jco.2000.18.22.3748","journal-title":"J Clin Oncol"},{"key":"6173_CR12","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1093\/jnci\/djj357","volume":"98","author":"D Mauri","year":"2006","unstructured":"Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 98:1285\u20131291. https:\/\/doi.org\/10.1093\/jnci\/djj357","journal-title":"J Natl Cancer Inst"},{"key":"6173_CR13","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520\u2013529. https:\/\/doi.org\/10.1056\/NEJMoa1109653","journal-title":"N Engl J Med"},{"key":"6173_CR14","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1158\/1078-0432.ccr-09-1823","volume":"16","author":"SR Johnston","year":"2010","unstructured":"Johnston SR (2010) New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 16:1979\u20131987. https:\/\/doi.org\/10.1158\/1078-0432.ccr-09-1823","journal-title":"Clin Cancer Res"},{"key":"6173_CR15","unstructured":"NCCN guidelined for patients (2020) Breast cancer Metastatic. https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/stage_iv_breast-patient.pdf. Accessed Dec 2020"},{"key":"6173_CR16","unstructured":"ESMO Clinical Practice Guidelines (2020) Advanced Breast Cancer. 4th ESO\u2013ESMO International Consensus Guidelines for Advanced Breast Cancer. https:\/\/www.esmo.org\/content\/download\/181639\/3308758\/1\/Clinical-Practice-Guidelines-Slideset-Advanced-Breast-Cancer.pdf. Accessed Dec 2020"},{"key":"6173_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111661","author":"V Rossi","year":"2019","unstructured":"Rossi V, Berchialla P, Giannarelli D, Nistic\u00f2 C, Ferretti G, Gasparro S, Russillo M, Catania G, Vigna L, Mancusi RL, Bria E, Montemurro F, Cognetti F, Fabi A (2019) Should all patients with HR-positive HER2-negative metastatic breast cancer receive CDK 4\/6 inhibitor as first-line based therapy? A network meta-analysis of data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON SWOG and FACT trials. Cancers. https:\/\/doi.org\/10.3390\/cancers11111661","journal-title":"Cancers"},{"key":"6173_CR18","doi-asserted-by":"publisher","first-page":"e900","DOI":"10.1634\/theoncologist.2019-0729","volume":"25","author":"AN Shah","year":"2020","unstructured":"Shah AN, Metzger O, Bartlett CH, Liu Y, Huang X, Cristofanilli M (2020) Hormone receptor-positive\/human epidermal growth receptor 2-negative metastatic breast cancer in young women: emerging data in the era of molecularly targeted agents. Oncologist 25:e900\u2013e908. https:\/\/doi.org\/10.1634\/theoncologist.2019-0729","journal-title":"Oncologist"},{"key":"6173_CR19","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/jco.2007.13.5822","volume":"26","author":"S Chia","year":"2008","unstructured":"Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26:1664\u20131670. https:\/\/doi.org\/10.1200\/jco.2007.13.5822","journal-title":"J Clin Oncol"},{"key":"6173_CR20","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1200\/jco.2010.28.8415","volume":"28","author":"A Di Leo","year":"2010","unstructured":"Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28:4594\u20134600. https:\/\/doi.org\/10.1200\/jco.2010.28.8415","journal-title":"J Clin Oncol"},{"key":"6173_CR21","doi-asserted-by":"publisher","first-page":"175883592094093","DOI":"10.1177\/1758835920940939","volume":"12","author":"P du Rusquec","year":"2020","unstructured":"du Rusquec P, Blonz C, Frenel JS, Campone M (2020) Targeting the PI3K\/Akt\/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer. Therapeutic Adv Med Oncol 12:1758835920940939. https:\/\/doi.org\/10.1177\/1758835920940939","journal-title":"Therapeutic Adv Med Oncol"},{"key":"6173_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/jco.2014.60.1971","volume":"34","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA 3rd, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER 3rd, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, Baselga J (2016) Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol 34:419\u2013426. https:\/\/doi.org\/10.1200\/jco.2014.60.1971","journal-title":"J Clin Oncol"},{"key":"6173_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.febslet.2009.11.041","volume":"584","author":"RL Yamnik","year":"2010","unstructured":"Yamnik RL, Holz MK (2010) mTOR\/S6K1 and MAPK\/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation. FEBS Lett 584:124\u2013128. https:\/\/doi.org\/10.1016\/j.febslet.2009.11.041","journal-title":"FEBS Lett"},{"key":"6173_CR24","doi-asserted-by":"publisher","first-page":"331s","DOI":"10.1158\/1078-0432.ccr-031212","volume":"10","author":"R Schiff","year":"2004","unstructured":"Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK (2004) Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10:331s\u2013336s. https:\/\/doi.org\/10.1158\/1078-0432.ccr-031212","journal-title":"Clin Cancer Res"},{"key":"6173_CR25","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1200\/JCO.2020.38.15_suppl.1006","volume":"38","author":"HS Rugo","year":"2020","unstructured":"Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Borrego MR, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner NC, Sophos N, Zarate JP, Arce C, Shen Y-M, Chia SKL (2020) Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2\u2013) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4\/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results. J Clin Oncol 38:1006\u20131006. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.1006","journal-title":"J Clin Oncol"},{"key":"6173_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4137\/bcbcr.s12443","volume":"10","author":"L Lousberg","year":"2016","unstructured":"Lousberg L, Jerusalem G (2016) Safety, efficacy, and patient acceptability of everolimus in the treatment of breast cancer. Breast Cancer 10:239\u2013252. https:\/\/doi.org\/10.4137\/bcbcr.s12443","journal-title":"Breast Cancer"},{"key":"6173_CR27","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1634\/theoncologist.2018-0077","volume":"23","author":"R Tancredi","year":"2018","unstructured":"Tancredi R, Furlanetto J, Loibl S (2018) Endocrine therapy in premenopausal hormone receptor positive\/human epidermal growth receptor 2 negative metastatic breast cancer: between guidelines and literature. Oncologist 23:974\u2013981. https:\/\/doi.org\/10.1634\/theoncologist.2018-0077","journal-title":"Oncologist"},{"key":"6173_CR28","doi-asserted-by":"publisher","first-page":"v107","DOI":"10.1093\/annonc\/mdz242.006","volume":"30","author":"J Jeong","year":"2019","unstructured":"Jeong J, Kim JE, Ahn JH, Jung KH, Koh SJ, Cheon J, Sohn J, Kim GM, Lee KS, Park IH, Sim SH, Kim SB (2019) 311PD - Leuprorelin (LEUP) combined with Letrozole (LET) with\/without everolimus (EVE) in ovarian suppressed premenopausal women with hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC): primary analysis of LEO trial (NCT02344550). Ann Oncol 30:v107. https:\/\/doi.org\/10.1093\/annonc\/mdz242.006","journal-title":"Ann Oncol"},{"key":"6173_CR29","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/annonc\/mdu009","volume":"25","author":"HS Rugo","year":"2014","unstructured":"Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G, Baselga J, Perez A, Geberth M, Csoszi T, Chouinard E, Srimuninnimit V, Puttawibul P, Eakle J, Feng W, Bauly H, El-Hashimy M, Taran T, Burris HA 3rd (2014) Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Annal Oncol 25:808\u2013815. https:\/\/doi.org\/10.1093\/annonc\/mdu009","journal-title":"Annal Oncol"},{"key":"6173_CR30","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/s1470-2045(17)30109-2","volume":"18","author":"HS Rugo","year":"2017","unstructured":"Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia C, Mayer IA, Meiller TF, Chambers MS, Sweetman RW, Sabo JR, Litton JK (2017) Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol 18:654\u2013662. https:\/\/doi.org\/10.1016\/s1470-2045(17)30109-2","journal-title":"Lancet Oncol"},{"key":"6173_CR31","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1200\/go.20.00081","volume":"6","author":"HL Gomez","year":"2020","unstructured":"Gomez HL, Casta\u00f1eda C, Valencia F, Mu\u00f1oz-Bermeo R, Torrico MDC, Neciosup S (2020) ABC4 consensus: first Latin American meeting-assessment, comments, and application of its recommendations. JCO Global Oncol 6:819\u2013827. https:\/\/doi.org\/10.1200\/go.20.00081","journal-title":"JCO Global Oncol"},{"key":"6173_CR32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.neo.2015.01.005","volume":"17","author":"GN Hortobagyi","year":"2015","unstructured":"Hortobagyi GN (2015) Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2. Neoplasia 17:279\u2013288. https:\/\/doi.org\/10.1016\/j.neo.2015.01.005","journal-title":"Neoplasia"},{"key":"6173_CR33","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Mart\u00edn M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Sondhi M, Wang Y, Chakravartty A, Rodriguez-Lorenc K, Taran T, Jerusalem G (2020) Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med 382:514\u2013524. https:\/\/doi.org\/10.1056\/NEJMoa1911149","journal-title":"N Engl J Med"},{"key":"6173_CR34","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martin M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G (2018) Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 36:2465\u20132472. https:\/\/doi.org\/10.1200\/JCO.2018.78.9909","journal-title":"J Clin Oncol"},{"key":"6173_CR35","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/jco.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A (2017) MONARCH 2: abemaciclib in combination with fulvestrant in women With HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 35:2875\u20132884. https:\/\/doi.org\/10.1200\/jco.2017.73.7585","journal-title":"J Clin Oncol"},{"key":"6173_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clbc.2019.06.017","volume":"20","author":"S Sammons","year":"2020","unstructured":"Sammons S, Shastry M, Dent S, Anders C, Hamilton E (2020) Practical treatment strategies and future directions after progression while receiving cdk4\/6 inhibition and endocrine therapy in advanced HR(+)\/HER2(-) breast cancer. Clin Breast Cancer 20:1\u201311. https:\/\/doi.org\/10.1016\/j.clbc.2019.06.017","journal-title":"Clin Breast Cancer"},{"key":"6173_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.010","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andr\u00e9 F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cort\u00e9s J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)(\u2020). Annal Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.010","journal-title":"Annal Oncol"},{"key":"6173_CR38","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, P\u00e1pai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380:1929\u20131940. https:\/\/doi.org\/10.1056\/NEJMoa1813904","journal-title":"N Engl J Med"},{"key":"6173_CR39","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Andr\u00e9 F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M (2018) Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 379:1926\u20131936. https:\/\/doi.org\/10.1056\/NEJMoa1810527","journal-title":"N Engl J Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06173-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06173-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06173-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T11:31:20Z","timestamp":1624620680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06173-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,16]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["6173"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06173-z","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,16]]},"assertion":[{"value":"28 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SA has received personal fees from Roche, Merck, Eli Lilly, Abdi Ibrahim AS, BMS, Novartis, Pfizer, Mustafa Nevzat \u0130la\u00e7 Sanayii. SBK has received grant from Novartis, Sanofi-Aventis, Kyowa-Kirin Inc, Dongkook Pharm Co, others from Novartis, Personal fees from Astra-Zeneca, Eli Lilly, Enzychem, Dae Hwa Pharmaceutical Co Ltd, ISU Abix, and Daiichi-Sankyo. KSL has received personal fees from Roche, Novartis, Lilly and nonfinancial support from Dong-A Pharm. SAI has received grant from AstraZeneca, Roche, Pfizer, personal fees from Novartis, and others from Amgen, Eisai, Hanmi, and Novartis. JB, KS, and HX are Novartis employees. FR owns Novartis stocks. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval was obtained at each participating center for the collection of the data described in this report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from each participant for inclusion in this research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}